Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
$538K Buy
16,171
+1,541
+11% +$56.3K ﹤0.01% 1935
2020
Q3
$470K Buy
14,630
+2,934
+25% +$84.3K ﹤0.01% 1841
2020
Q2
$322K Buy
11,696
+613
+6% +$14.5K ﹤0.01% 1990
2020
Q1
$178K Sell
11,083
-639
-5% -$15.1K ﹤0.01% 2119
2019
Q4
$280K Buy
+11,722
New +$238K ﹤0.01% 2092
2019
Q3
Sell
-11,402
Closed -$292K 2525
2019
Q2
$292K Buy
11,402
+1,977
+21% +$55.1K ﹤0.01% 2032
2019
Q1
$274K Buy
+9,425
New +$244K ﹤0.01% 2045
2018
Q1
Sell
-11,527
Closed -$359K 2256
2017
Q4
$359K Buy
+11,527
New +$341K ﹤0.01% 1859

Other funds holding INSM

Aperio Group's INSM Position: Q4 2020 in Review

Aperio Group increased its Insmed (INSM) stake by 11% in Q4 2020, buying an estimated $56.3K and bringing the position to 16,171 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #1935.

Aperio Group first reported a position in INSM in Q4 2017 and has held it in 8 quarters since. 206 funds tracked by Wall St. Rank hold INSM as of Q4 2020.

  • Aperio Group held 16,171 shares of Insmed worth $538K as of Q4 2020.
  • Aperio Group bought 1,541 Insmed shares in Q4 2020, an estimated $56.3K.
  • Insmed made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1935 holding.
  • Aperio Group first reported a position in Insmed in Q4 2017 and has held it in 8 quarters since.
  • 206 funds tracked by Wall St. Rank held Insmed as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.